In March 2025, the company declared new options for a immediate-to-buyer offering of its Wegovy weight loss drug. The company proven a new pharmacy, referred to as NovoCare, which might cost consumers $499 every month for entry to the drug, under 50 % the expense of the drug via other pharmaceutical distribution networks.[fifty three]Novo Nordisk A